Ipilimumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, ipilimumab enhances the body's immune response against tumor cells.
